AKEBIA THERAPEUTICS, INC. Cost, Direct Material
AKEBIA THERAPEUTICS, INC. (AKBA) reported Cost, Direct Material of $18.00 million for the 3-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostDirectMaterial · last filed 2022-03-01
- AKEBIA THERAPEUTICS, INC. cost, direct material for the quarter ending 2021-12-31 was $18.00M.
- AKEBIA THERAPEUTICS, INC. cost, direct material for the quarter ending 2021-06-30 was $30.30M.
| Period end | Cost, Direct Material 3 month |
|---|---|
| 2021-12-31 | $18.00M 10-K · filed 2022-03-01 |
| 2021-06-30 | $30.30M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |